Europe’s Widening Gap Between Approval and Access

João L. Carapinha, Ph.D.

Table of Contents

Poll 31 – 2026

7
Europe’s Widening Gap Between Approval and Access

I’ve been reflecting on how Europe continues to lose ground in pharmaceutical investment and clinical research, while patients face longer waits and lower access to new medicines. The upcoming EMA-EFPIA meeting highlights a sector under pressure. If Europe wants to reverse this trend, what should be the top priority? Share your insights by voting below!

 

What should be the top priority to improve Europe’s pharmaceutical competitiveness and patient access?

Table of Contents